ADVERTISEMENT
News
VENDAJE - BioStem Technologies
08/26/2024
BioStem has registered a 60-patient study to evaluate the safety and efficacy of human placental allograft BR-AM (Vendaje) + SoC vs SoC only in the treatment of DFUs. Primary outcome measures 100% re-epithelialization over a 12-week period. Est study completion 1/26. clinicaltrials.gov
